Enliven Therapeutics develops small molecule drugs, led by an investigational kinase inhibitor for chronic myeloid leukemia. It last closed at $46.53 on Nov 20, up 0.26% on the day. The next earnings report for ELVN is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, ELVN reported EPS of -$0.36. Over its last 8 reports the stock moved an average of 3.8% the session after earnings. Over the last 12 months ELVN insiders bought $0 of stock on the open market and sold $76.4M, according to SEC Form 4 filings.
AI Auto Pilots
Is ELVN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ELVN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ELVNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ELVN · as of the Nov 20 close · updated each morning
Uptrend
The stock sits between its 20 and 50 day averages. It is 5% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 50). The nearest support is the Pivot S1 at $45.50, and the nearest resistance the Pivot at $46.67.
Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 4.8%/day
Key levels
$62.3252 week high+33.9%
$50.77100 day average+9.1%
$47.69Pivot R1+2.5%
$47.36Swing high (Jun 12)+1.8%
$46.6820 day average+0.3%
$46.67Pivot+0.3%
$46.53Last close
$45.50Pivot S1−2.2%
$45.3450 day average−2.6%
$44.31200 day average−4.8%
$44.17Swing low (Sep 25)−5.1%
$14.7952 week low−68.2%
Indicators
RSI (14)
50.43
Middle of its range
Neutral
MACD
0.58
Below its signal line
Bearish
Stochastic
27.6
Middle of its range
Neutral
ADX (14)
21.5
Weak trend
Williams %R
-71.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
2.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−5.9%
Change over 10 sessions
Bearish
ATR (14)
$2.23
Typical daily range, 4.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
Rising
Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 11.3%/day
Key levels
$62.3252 week high+33.9%
$50.77100 day average+9.1%
$47.69Pivot R1+2.5%
$47.36Swing high (Jun 12)+1.8%
$46.6820 day average+0.3%
$46.67Pivot+0.3%
$46.53Last close
$45.50Pivot S1−2.2%
$45.3450 day average−2.6%
$44.31200 day average−4.8%
$44.17Swing low (Sep 25)−5.1%
$14.7952 week low−68.2%
Indicators
RSI (14)
50.40
Middle of its range
Neutral
MACD
0.74
Below its signal line
Bearish
Stochastic
44.9
Middle of its range
Neutral
ADX (14)
29.1
Trending up
Williams %R
-61.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-48.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−14.3%
Change over 10 sessions
Bearish
ATR (14)
$5.27
Typical daily range, 11.3% of price
MA 10Above
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for ELVN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ELVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ELVN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ELVNHow many large options trades hit ELVN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ELVN in the last 90 days.
From SEC Form 4 filings by ELVN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELVN is in one of them and how their past ELVN trades turned out.
Enliven Therapeutics is a biopharmaceutical company based in Burlingame, California, that develops small molecule drugs. Its lead candidate, ELVN-001, is a kinase inhibitor being studied for chronic myeloid leukemia, a blood cancer, in patients whose disease has become resistant or intolerant to existing treatments. The company also runs research programs on other targeted therapies aimed at unmet medical needs.